Showing results (181-190 of 829) with videos related to
Sort By:
Pageof 83
Diabetes Care|December 28, 2002
Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over studyKasper Rossing, Per K Christensen, Birgitte V Hansen, et al.Diabetes Care|February 28, 2004
Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetesLise Tarnow, Peter Hovind, Tom Teerlink, et al.Kidney International|August 18, 2005
Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuriaKasper Rossing, Katrine J Schjoedt, Berit R Jensen, et al.Frontiers in Pharmacology|May 16, 2022
Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator ReceptorViktor Rotbain Curovic, Morten B Houlind, Tine W Hansen, et al.Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|February 16, 2012
Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)Hans-Henrik Parving, Barry M Brenner, John J V McMurray, et al.Diabetes Care|May 25, 2019
Utility of Plasma Concentration of Trimethylamine N-Oxide in Predicting Cardiovascular and Renal Complications in Individuals With Type 1 DiabetesSigne A Winther, Jens C Øllgaard, Nete Tofte, et al.Diabetes Care|March 20, 2019
Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 DiabetesViktor Rotbain Curovic, Simone Theilade, Signe A Winther, et al.Immunobiology|March 22, 2024
Effect of dapagliflozin on collectins and complement activation in plasma from patients with type 2 diabetes and albuminuria: Data from the DapKid cohortMia Jensen, Mie K Eickhoff, Frederik Persson, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 12, 2021
HbA1c and beyondPeter RossingKidney International Supplements|May 9, 2022
Clinical perspective-evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetesPeter RossingPageof 83